Abstract
There is evidence for the efficacy of noradrenaline and serotonin reuptake inhibitors treating attention-deficit hyperactivity disorder (ADHD). In this open trial, we checked St. John's wort, a serotonin and noradrealine reuptake inhibitor, and actually used as an antidepressant, for this indication. Three 14–16-year-old male psychiatric outpatients, diagnosed with ADHD have been rated at baseline and while taking St. John's wort or a placebo, respectively, by the Conner Scale and by the Continuous Performance Test, to determine its efficacy as a treatment option for ADHD. Patients’ mean scores improved for Conners’ hyperactivity, inattention and immaturity factors. Although the sample size is very small and therefore generalisation is very difficult, this observation indicates that St. John's wort might be a slightly effective treatment for ADHD also.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
